Drug Profile
mRNA 5671
Alternative Names: KRAS vaccine - Moderna Therapeutics; mRNA-5671; Mutant KRAS vaccine - Moderna Therapeutics; V 941Latest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 22 Sep 2022 mRNA 5671 is still in phase I trials for Non-small cell lung cancer, Colorectal cancer, Pancreatic cancer in the USA (NCT03948763)
- 25 Aug 2022 Merck Sharp & Dohme completes the phase I V941-001 trial for Non-small cell lung cancer, Colorectal cancer, Pancreatic cancer (Metastatic disease, Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) (IM, Injection) (NCT03948763)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IM)